EUVIMEDEUVIMED entdecken
Open Access

Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer

Yoshihiro Nakagami, Toshiki Mugita, Masahiro Kurokawa, Sho Okada, Tatsuki Inoue, Kazuhiko Oshinomi, Masakazu Nagata, Takashi Fukagai

Cureus · 05.05.2025

DOI: 10.7759/cureus.83494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 05.05.2025. Verfasst von Yoshihiro Nakagami und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Showa University, Tokyo, JPN. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Abiraterone acetate is indicated for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). However, abiraterone acetate is significantly associated with drug-induced liver injury (DILI). In this study, we report severe cases of abiraterone acetate-induced liver injury in patients with prostate cancer. METHODS: This retrospective study uses medical records from September 2014 to November 2023. During this period, abiraterone acetate was administered to 126 patients at the Showa University Hospital in Japan. Of these, 113 patients were included in this study for analysis of the incidence of DILI. The incidence, timing, grade, and treatment of abiraterone-induced liver injury were investigated. RESULTS: The median age of the included patients was 76 years. There were 32 cases of upfront therapy, 63 cases of pre-docetaxel therapy, and 18 cases of post-docetaxel therapy. Seven patients had ≥ grade 3 DILIs and comprised three cases of upfront therapy, three of pre-docetaxel therapy, and one of post-docetaxel therapy. There were four cases of the hepatocellular type and three cases of the cholestatic type of DILI. Liver injury developed in all cases from the fourth week to the eighth week since drug administration. Abiraterone acetate was immediately discontinued in all patients with liver injury. The incidence of DILI in the upfront therapy group of this study was significantly higher. Liver metastases (OR = 6.667, p = 0.043, 95% CI (1.063-41.773)) and gamma-glutamyl transpeptidase levels (OR = 7.556, p = 0.013, 95% CI (1.534-37.214)) were significantly associated with grade ≥ 3 DILI in a single logistic regression analysis. CONCLUSION: Severe DILI is a potential complication of the administration of abiraterone acetate. We recommend close monitoring for liver injury during abiraterone acetate therapy, especially in the first few months.

Schlagwörter

Stichwörter der Autor:innen

abiraterone acetatedrug-induced liver injurymetastatic castration-resistant prostate cancermetastatic hormone-sensitive prostate cancerr ratio

Autor:innen und Institutionen

  • Department of Urology, Showa University, Tokyo, JPN.

Zitieren

APA

Nakagami, Y., Mugita, T., Kurokawa, M., Okada, S., Inoue, T., Oshinomi, K., Nagata, M., & Fukagai, T. (2025). Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer. Cureus. https://doi.org/10.7759/cureus.83494

Vancouver

Nakagami Y, Mugita T, Kurokawa M, Okada S, Inoue T, Oshinomi K, et al. Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer. Cureus. 2025. doi:10.7759/cureus.83494

BibTeX
@article{Nakagami2025,
  author = {Nakagami, Yoshihiro and Mugita, Toshiki and Kurokawa, Masahiro and Okada, Sho and Inoue, Tatsuki and Oshinomi, Kazuhiko and Nagata, Masakazu and Fukagai, Takashi},
  title = {Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer},
  journal = {Cureus},
  year = {2025},
  doi = {10.7759/cureus.83494}
}
Kostenlos starten →